New drug combo shows promise in ovarian cancer safety trial

NCT ID NCT05276973

First seen Jan 04, 2026 · Last updated May 10, 2026 · Updated 21 times

Summary

This early-phase study tested adding the experimental drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to find the safest dose and check for side effects. About 25 participants took part, and the results will help decide if this combination is worth testing in larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Augusta University Medical Center

    Augusta, Georgia, 30912, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • UCSF Medical Center-Mission Bay

    San Francisco, California, 94158, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • Virginia Commonwealth University/Massey Cancer Center

    Richmond, Virginia, 23298, United States

  • Women and Infants Hospital

    Providence, Rhode Island, 02905, United States

Conditions

Explore the condition pages connected to this study.